Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Michael D JainJay Y SpiegelLoretta J NastoupilJohn S TamaresisArmin GhobadiYi LinLazaros LekakisPatrick ReaganOlalekan O OluwoleJoseph P McGuirkAbhinav DeolKathleen A DorritieAlison R SehgalAndre H GoyBrian T HillCharalambos AndreadisJavier L MuñozMatthew L UlricksonJason R WestinJulio C ChavezDilan A PatelMiriam T JacobsRadhika BansalN Nora BennaniVivek G PatelAaron P RapoportJulie M VoseDavid Bernard MiklosSattva S NeelapuFrederick L LockeMatthew LunningSaurabh DahiyaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.